Literature DB >> 19811099

Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance.

In-Gyu Bae1, Jerome J Federspiel, José M Miró, Christopher W Woods, Lawrence Park, Michael J Rybak, Thomas H Rude, Suzanne Bradley, Suzana Bukovski, Cristina Garcia de la Maria, Souha S Kanj, Tony M Korman, Francesc Marco, David R Murdoch, Patrick Plesiat, Marta Rodriguez-Creixems, Porl Reinbott, Lisa Steed, Pierre Tattevin, Marie-Françoise Tripodi, Karly L Newton, G Ralph Corey, Vance G Fowler.   

Abstract

BACKGROUND: The significance of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) is unknown. Using a multinational collection of isolates from methicillin-resistant S. aureus (MRSA) infective endocarditis (IE), we characterized patients with IE with and without hVISA, and we genotyped the infecting strains.
METHODS: MRSA bloodstream isolates from 65 patients with definite IE from 8 countries underwent polymerase chain reaction (PCR) for 31 virulence genes, pulsed-field gel electrophoresis, and multilocus sequence typing. hVISA was defined using population analysis profiling.
RESULTS: Nineteen (29.2%) of 65 MRSA IE isolates exhibited the hVISA phenotype by population analysis profiling. Isolates from Oceania and Europe were more likely to exhibit the hVISA phenotype than isolates from the United States (77.8% and 35.0% vs 13.9%; P < .001). The prevalence of hVISA was higher among isolates with a vancomycin minimum inhibitory concentration of 2 mg/L (P = .026). hVISA-infected patients were more likely to have persistent bacteremia (68.4% vs 37.0%; P = .029) and heart failure (47.4% vs 19.6%; P = .033). Mortality did not differ between hVISA- and non-hVISA-infected patients (42.1% vs 34.8%, P = .586). hVISA and non-hVISA isolates were genotypically similar.
CONCLUSIONS: In these analyses, the hVISA phenotype occurred in more than one-quarter of MRSA IE isolates, was associated with certain IE complications, and varied in frequency by geographic region.

Entities:  

Mesh:

Year:  2009        PMID: 19811099      PMCID: PMC3600359          DOI: 10.1086/606027

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  49 in total

1.  Vancomycin heteroresistance and methicillin-resistant Staphylococcus aureus.

Authors:  Stan Deresinski
Journal:  J Infect Dis       Date:  2009-03-01       Impact factor: 5.226

2.  Incidence and characteristics of vancomycin nonsusceptible strains of methicillin-resistant Staphylococcus aureus at Hershey Medical Center.

Authors:  Klaudia Kosowska-Shick; Lois M Ednie; Pamela McGhee; Kathy Smith; Cynthia D Todd; Amanda Wehler; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2008-10-06       Impact factor: 5.191

3.  Genotypic characteristics of Staphylococcus aureus isolates from a multinational trial of complicated skin and skin structure infections.

Authors:  Steven J Campbell; Hitesh S Deshmukh; Charlotte L Nelson; In-Gyu Bae; Martin E Stryjewski; Jerome J Federspiel; Giang T Tonthat; Thomas H Rude; Steven L Barriere; Ralph Corey; Vance G Fowler
Journal:  J Clin Microbiol       Date:  2007-12-12       Impact factor: 5.948

4.  Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.

Authors:  Francesc Marco; Cristina García de la Mària; Yolanda Armero; Eurídice Amat; Dolors Soy; Asunción Moreno; Ana del Río; Manel Almela; Carlos A Mestres; José M Gatell; María Teresa Jiménez de Anta; José M Miró
Journal:  Antimicrob Agents Chemother       Date:  2008-04-21       Impact factor: 5.191

5.  Associations between the genotypes of Staphylococcus aureus bloodstream isolates and clinical characteristics and outcomes of bacteremic patients.

Authors:  Tahaniyat Lalani; Jerome J Federspiel; Helen W Boucher; Thomas H Rude; In-Gyu Bae; Michael J Rybak; Giang T Tonthat; G Ralph Corey; Martin E Stryjewski; George Sakoulas; Vivian H Chu; Jeff Alder; Judith N Steenbergen; Steven A Luperchio; Marilyn Campion; Christopher W Woods; Vance G Fowler
Journal:  J Clin Microbiol       Date:  2008-07-02       Impact factor: 5.948

6.  Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin.

Authors:  T P Lodise; J Graves; A Evans; E Graffunder; M Helmecke; B M Lomaestro; K Stellrecht
Journal:  Antimicrob Agents Chemother       Date:  2008-06-30       Impact factor: 5.191

7.  Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides.

Authors:  Steven N Leonard; Kerri L Rossi; Karly L Newton; Michael J Rybak
Journal:  J Antimicrob Chemother       Date:  2009-01-09       Impact factor: 5.790

8.  Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007).

Authors:  Michael J Rybak; Steve N Leonard; Kerri L Rossi; Chrissy M Cheung; Helio S Sader; Helio S Sadar; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2008-07-16       Impact factor: 5.948

9.  Impact of inoculum size and heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) on vancomycin activity and emergence of VISA in an in vitro pharmacodynamic model.

Authors:  Warren E Rose; Steven N Leonard; Kerri L Rossi; Glenn W Kaatz; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2008-11-17       Impact factor: 5.191

10.  Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia.

Authors:  Yasmin Maor; Michal Hagin; Natasha Belausov; Nathan Keller; Debbi Ben-David; Galia Rahav
Journal:  J Infect Dis       Date:  2009-03-01       Impact factor: 5.226

View more
  55 in total

1.  An association between bacterial genotype combined with a high-vancomycin minimum inhibitory concentration and risk of endocarditis in methicillin-resistant Staphylococcus aureus bloodstream infection.

Authors:  Clare E Miller; Rahul Batra; Ben S Cooper; Amita K Patel; John Klein; Jonathan A Otter; Theodore Kypraios; Gary L French; Olga Tosas; Jonathan D Edgeworth
Journal:  Clin Infect Dis       Date:  2011-12-20       Impact factor: 9.079

2.  USA600 (ST45) methicillin-resistant Staphylococcus aureus bloodstream infections in urban Detroit.

Authors:  Carol L Moore; Paola Osaki-Kiyan; Marybeth Perri; Susan Donabedian; Nadia Z Haque; Anne Chen; Marcus J Zervos
Journal:  J Clin Microbiol       Date:  2010-03-24       Impact factor: 5.948

Review 3.  Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates.

Authors:  Sebastiaan J van Hal; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

Review 4.  Evolving resistance among Gram-positive pathogens.

Authors:  Jose M Munita; Arnold S Bayer; Cesar A Arias
Journal:  Clin Infect Dis       Date:  2015-09-15       Impact factor: 9.079

5.  Successful treatment of vancomycin-intermediate Staphylococcus aureus pacemaker lead infective endocarditis with telavancin.

Authors:  Luis A Marcos; Bernard C Camins
Journal:  Antimicrob Agents Chemother       Date:  2010-09-27       Impact factor: 5.191

6.  Influence of vancomycin minimum inhibitory concentration on the outcome of methicillin-susceptible Staphylococcus aureus left-sided infective endocarditis treated with antistaphylococcal β-lactam antibiotics: a prospective cohort study by the International Collaboration on Endocarditis.

Authors:  J M Pericàs; J A Messina; C Garcia-de-la-Mària; L Park; B K Sharma-Kuinkel; F Marco; D Wray; Z A Kanafani; M Carugati; E Durante-Mangoni; P Tattevin; V H Chu; A Moreno; V G Fowler; J M Miró
Journal:  Clin Microbiol Infect       Date:  2017-02-01       Impact factor: 8.067

Review 7.  Antimicrobial heteroresistance: an emerging field in need of clarity.

Authors:  Omar M El-Halfawy; Miguel A Valvano
Journal:  Clin Microbiol Rev       Date:  2015-01       Impact factor: 26.132

8.  Evaluation of vancomycin susceptibility testing for methicillin-resistant Staphylococcus aureus: comparison of Etest and three automated testing methods.

Authors:  Michael J Rybak; Celine Vidaillac; Helio S Sader; Paul R Rhomberg; Hossein Salimnia; Lawrence E Briski; Audrey Wanger; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2013-04-17       Impact factor: 5.948

9.  Outcomes of Vancomycin plus a β-Lactam versus Vancomycin Only for Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia.

Authors:  James Truong; John J Veillette; Steve C Forland
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

10.  Mechanisms of NDV-3 vaccine efficacy in MRSA skin versus invasive infection.

Authors:  Michael R Yeaman; Scott G Filler; Siyang Chaili; Kevin Barr; Huiyuan Wang; Deborah Kupferwasser; John P Hennessey; Yue Fu; Clint S Schmidt; John E Edwards; Yan Q Xiong; Ashraf S Ibrahim
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.